CRISPR Therapeutics Expands Casgevy Label to Pediatric Patients as Q2 Sales Hit $76M
Question
CRISPR Therapeutics Expands Casgevy Label to Pediatric Patients as Q2 Sales Hit $76M
Direct answer
CRISPR Therapeutics saw commercial acceleration for Casgevy, with second-quarter revenue reaching $76 million, a 78% quarter-over-quarter increase. The therapy received FDA approval to expand its label to pediatric patients aged 2 and older, broadening the commercial pool for hemoglobinopathy treatments in partnership with Vertex Pharmaceuticals. — bullish pressure on CRSP.
- Original publisher
- Market Ontology
- Evidence through
- 2026-09-09
- Published
- 2026-10-20
- Revision
- 1 · 2026-10-20
Cite as: Market Ontology, “CRISPR Therapeutics Expands Casgevy Label to Pediatric Patients as Q2 Sales Hit $76M”, revision 1, evidence through 2026-09-09. https://marketontology.com/catalysts/2026-09-09/crispr-therapeutics-expands-casgevy-label-to-pediatric-patients-as-q2-sales-hit-73b53d
| Asset | Direction | Timeframe | Channel | Score |
|---|---|---|---|---|
| CRSP | ▲Bull | 1–3 months | Policy Shift | 74 |
CRISPR Therapeutics Expands Casgevy Label to Pediatric Patients as Q2 Sales Hit $76M
CRISPR Therapeutics saw commercial acceleration for Casgevy, with second-quarter revenue reaching $76 million, a 78% quarter-over-quarter increase. The therapy received FDA approval to expand its label to pediatric patients aged 2 and older, broadening the commercial pool for hemoglobinopathy treatments in partnership with Vertex Pharmaceuticals. — bullish pressure on CRSP.
CRISPR Therapeutics saw commercial acceleration for Casgevy, with second-quarter revenue reaching $76 million, a 78% quarter-over-quarter increase. The therapy received FDA approval to expand its label to pediatric patients aged 2 and older, broadening the commercial pool for hemoglobinopathy treatments in partnership with Vertex Pharmaceuticals.
- SummaryCRISPR Therapeutics saw commercial acceleration for Casgevy, with second-quarter revenue reaching $76 million, a 78% quarter-over-quarter increase. The therapy received FDA approval to expand its label to pediatric patients aged 2 and older, broadening the commercial pool for hemoglobinopathy treatments in partnership with Vertex Pharmaceuticals.
- CRSPDirect directional exposure
Illustrative, not advice
- Crowded positioning may already reflect the move
- Counter-catalyst could neutralize the thesis before window closes
- CRSP closes below pre-catalyst level on rising volume
- Catalyst narrative is officially walked back or contradicted
- Cross-asset confirmation (rates / FX / vol) reverses direction
- CRSP price vs. pre-event level
- CRSP volume vs. 20-day average
What happened next
Price follow-up pending — no stored daily closes for these assets yet.
Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.
No verifiable public source recorded for this card.
Related catalysts
- 2026-09-09CRISPR Therapeutics Casgevy Sales Surge 78% QoQ to $76M Following FDA ExpansionCRSP VRTX-1.51%
- 2026-09-09CRISPR Therapeutics Casgevy Revenue Surges 78% QoQ to $76M on Pediatric LabelCRSP VRTX XBI-2.38%
- 2026-09-09CRISPR Therapeutics Gains FDA Pediatric Approval for Casgevy as Sales Hit $76MCRSP VRTX-1.51%
- 2026-09-09CRISPR Therapeutics reports 78 percent QoQ Casgevy sales growth to $76MCRSP VRTX-1.51%
- 2026-09-09CRISPR Therapeutics Expands Casgevy Label to Pediatric Patients as Q2 Sales Hit $76MCRSP VRTX-1.51%
- 2026-09-09CRISPR Therapeutics Expands Casgevy Label to Pediatric Patients as Q2 Sales Hit $76MCRSP VRTX-1.51%
- 2026-09-09CRISPR Therapeutics Expands Casgevy Label to Pediatric Patients Aged 2+CRSP VRTX-1.51%
- 2026-09-09CRISPR Therapeutics Expands Casgevy Label to Pediatric Patients as Q2 Sales Hit $76MCRSP VRTX-1.51%
See today's live cards
Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.